Terns Pharmaceuticals Receives Analyst Backing After Positive Drug Data
Terns Pharmaceuticals saw analyst support with Truist and Mizuho reiterating buy ratings after Phase 1 data for its CML drug TERN-701 showed a 64% response rate, with shares up over 300% in three months.